Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 17, 2025JACC Heart FailureOpen Access

Frailty and Effects of Semaglutide in Obesity-Related HFpEF

View Full Paper
Ask AI
Bookmark
Share

Authors

APAmbarish PandeyDKDalane W KitzmanKCKhaja Chinnakondepalli

Discussion

Loading...

Member takes

Overview

Pooled analysis of semaglutide effects on heart failure and frailty in obese individuals with HFpEF, suggesting significant symptom improvements.

Key Points

  • Semaglutide led to significant improvements in heart failure symptoms in the most frail participants over 52 weeks.
  • Weight loss achieved through semaglutide was consistent across different frailty levels, with no significant interaction.
  • Pooling analysis from the STEP-HFpEF program assessed efficacy across three baseline frailty groups in 1,145 obese heart failure patients.
  • Semaglutide reduced the burden of frailty, making participants more likely to transition to a nonfrail state after 52 weeks of treatment.

Cite This Study

Pandey et al. (2025) studied this question.

synapsesocial.com/papers/68d4605931b076d99fa5fe1ehttps://doi.org/10.1016/j.jchf.2025.102610
View Full Paper
Ask AI
Bookmark
Share